| Frataxin activates mitochondrial energy conversion and oxidative phosphorylation M Ristow, MF Pfister, AJ Yee, M Schubert, L Michael, CY Zhang, K Ueki, ... Proceedings of the National Academy of Sciences 97 (22), 12239-12243, 2000 | 280 | 2000 |
| Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial AJ Yee, WI Bensinger, JG Supko, PM Voorhees, JG Berdeja, ... The Lancet Oncology 17 (11), 1569-1578, 2016 | 188 | 2016 |
| Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ... Journal of clinical oncology 36 (9), 859, 2018 | 161 | 2018 |
| Genetic interrogation of circulating multiple myeloma cells at single-cell resolution JG Lohr, S Kim, J Gould, B Knoechel, Y Drier, MJ Cotton, D Gray, N Birrer, ... Science translational medicine 8 (363), 363ra147-363ra147, 2016 | 142 | 2016 |
| Human cochlear expressed sequence tags provide insight into cochlear gene expression and identify candidate genes for deafness AB Skvorak, Z Weng, AJ Yee, NG Robertson, CC Morton Human molecular genetics 8 (3), 439-452, 1999 | 98 | 1999 |
| Myeloma and bone disease C Panaroni, AJ Yee, NS Raje Current osteoporosis reports 15, 483-498, 2017 | 83 | 2017 |
| Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients AJ Yee, NS Raje Clinical interventions in aging, 331-338, 2012 | 66 | 2012 |
| Panobinostat and multiple myeloma in 2018 AJ Yee, NS Raje The oncologist 23 (5), 516-517, 2018 | 62 | 2018 |
| Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy CG Patel, AJ Yee, TA Scullen, N Nemani, L Santo, PG Richardson, ... Clinical Cancer Research 20 (15), 3955-3961, 2014 | 46 | 2014 |
| Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide AJ Yee, P Hari, R Marcheselli, AK Mahindra, DD Cirstea, TA Scullen, ... British journal of haematology 166 (3), 401-409, 2014 | 43 | 2014 |
| Denosumab for the treatment of bone disease in solid tumors and multiple myeloma AJ Yee, NS Raje Future Oncology 14 (3), 195-203, 2018 | 33 | 2018 |
| Advances in supportive care for multiple myeloma NS Raje, AJ Yee, GD Roodman Journal of the National Comprehensive Cancer Network 12 (4), 502-511, 2014 | 24 | 2014 |
| Selective HDAC6 inhibitor ACY-241, an oral tablet, combined with pomalidomide and dexamethasone: safety and efficacy of escalation and expansion cohorts in patients with … R Niesvizky, PG Richardson, AJ Yee, AK Nooka, MS Raab, KH Shain, ... Blood 128 (22), 3307, 2016 | 17 | 2016 |
| Ricolinostat (ACY-1215), the first selective HDAC6 inhibitor, in combonation with lenalidomide and dexamethasone in patients with relapsed and relapsed-and-refractory multiple … AJ Yee, W Bensinger, PM Voorhees, JG Berdeja, PG Richardson, ... Blood 126 (23), 3055, 2015 | 15 | 2015 |
| Ricolinostat (ACY-1215), a selective HDAC6 inhibitor, in combination with lenalidomide and dexamethasone: results of a phase 1b trial in relapsed and relapsed refractory … AJ Yee, PM Voorhees, W Bensinger, JG Berdeja, JG Supko, ... Blood 124 (21), 4772, 2014 | 15 | 2014 |
| Sequencing of nontransplant treatments in multiple myeloma patients with active disease AJ Yee, NS Raje Hematology 2014, the American Society of Hematology Education Program Book …, 2016 | 12 | 2016 |
| Clinical grade “SNaPshot” genetic mutation profiling in multiple myeloma E O'Donnell, A Mahindra, AJ Yee, V Nardi, N Birrer, N Horick, D Borger, ... EBioMedicine 2 (1), 71-73, 2015 | 11 | 2015 |
| Plasma cell dyscrasias AJ Yee, KM Winkfield, NS Raje Radiation Medicine Rounds: Hematologic Malignancies. New York: Demos Medical …, 2012 | 11 | 2012 |
| Initial results of a phase 1/2a, dose escalation study of PVX-410 multi-peptide cancer vaccine in patients with smoldering multiple myeloma (SMM) ML Wang, AK Nooka, AJ Yee, SK Thomas, E O’Donnell, J Shah, ... Blood 124 (21), 4737, 2014 | 7 | 2014 |
| Biomarker correlation with outcomes in patients with relapsed or refractory multiple myeloma on a phase I study of everolimus in combination with lenalidomide AJ Yee, AK Mahindra, PG Richardson, DD Cirstea, TA Scullen, SJ Rodig, ... Blood 118 (21), 3966, 2011 | 5 | 2011 |
